老年人中阿尔茨海默氏症风险标志物的日常体力活动差异
Francesca R Marino1,2, Jennifer A Deal1,3, Ryan J Dougherty4
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
概括
阿尔茨海默病 (AD) 风险标志物如β-粉样蛋白 (Aβ) 可能会改变老年人的日常体力活动模式. 活动量减少和夜间和晚上的变化是潜在的早期指标.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
背景情况:
- 每天的体力活动模式可以表明阿尔茨海默病 (AD) 风险.
- 了解早期活动中断对于AD检测至关重要.
- 在没有认知障碍的个体中,AD风险标志物 (Aβ,APOE-ε4) 和客观测量的活动之间的关联尚未得到充分理解.
研究的目的:
- 研究已确定的阿尔茨海默病 (AD) 风险标志物,β-粉样蛋白 (Aβ) 和阿波利波蛋白E-ε4 (APOE-ε4) 与客观测量的日常体力活动模式之间的关系.
- 为了确定这些AD风险标志物是否与认知不受损的老年人活动量,可变性或碎片化的差异有关.
主要方法:
- 利用手腕加速度计客观地测量了来自巴尔的摩老龄化纵向研究的参与者的身体活动.
- 收集关于大脑β-粉样蛋白 (Aβ) 状态和阿波利波蛋白E-ε4 (APOE-ε4) 基因型的数据.
- 采用调整后的线性和函数对梯度回归模型来分析Aβ/APOE-ε4状态和活动模式之间的横截面关联,考虑一天中的时间.
主要成果:
- 仅基于Aβ或APOE-ε4状态,没有观察到活动模式的整体差异.
- β-粉样蛋白阳性 (Aβ+) 与减少总体体力活动量和较低的白天内变异性有关,特别是在夜间和晚上早些时候.
- 携带APOE-ε4的人晚上活动量较高,但早上活动变化较低. 在Aβ+个体中,观察到日间活动曲线变淡,特别是当包括轻度认知障碍/痴呆症时.
结论:
- 在没有认知障碍的老年人中,β-粉样蛋白阳性 (Aβ+) 可能与每日体力活动量和可变性降低有关,特别是在夜间和晚上.
- 这些发现表明,身体活动模式的微妙变化可能是AD病理学的早期指标.
- 建议对更大的队列和多种多样的AD生物标志物进行进一步研究,以验证这些观察结果并跟踪纵向变化.
更多相关视频
08:07Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test
Published on: November 23, 2019
11.1K
04:13Using a Real-Time Locating System to Measure Walking Activity Associated with Wandering Behaviors Among Institutionalized Older Adults
Published on: February 8, 2019
6.8K
相关概念视频
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Dementia
112
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
112
